| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.
|
Schizophr Bull
|
2009
|
4.69
|
|
2
|
Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
|
Am J Psychiatry
|
2007
|
2.26
|
|
3
|
Improvement in psychotic symptoms after a gluten-free diet in a boy with complex autoimmune illness.
|
Am J Psychiatry
|
2015
|
2.01
|
|
4
|
Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers.
|
Drug Alcohol Depend
|
2010
|
1.39
|
|
5
|
Prevalence of celiac disease and gluten sensitivity in the United States clinical antipsychotic trials of intervention effectiveness study population.
|
Schizophr Bull
|
2009
|
1.39
|
|
6
|
Fluoxetine augmentation of haloperidol in chronic schizophrenia.
|
J Clin Psychopharmacol
|
2003
|
1.37
|
|
7
|
Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC.
|
Clin Chem
|
2009
|
1.28
|
|
8
|
Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial.
|
Neuropsychopharmacology
|
2011
|
1.20
|
|
9
|
Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration.
|
Clin Chem
|
2010
|
1.19
|
|
10
|
Neurologic and psychiatric manifestations of celiac disease and gluten sensitivity.
|
Psychiatr Q
|
2012
|
1.13
|
|
11
|
The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study.
|
J Clin Psychopharmacol
|
2003
|
1.10
|
|
12
|
Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study.
|
Schizophr Res
|
2013
|
1.08
|
|
13
|
Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study.
|
Schizophr Res
|
2011
|
1.08
|
|
14
|
Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects.
|
Isr J Psychiatry Relat Sci
|
2005
|
1.07
|
|
15
|
Comparison of clozapine use in Maryland and in Victoria, Australia.
|
Psychiatr Serv
|
2005
|
1.05
|
|
16
|
A review of anti-inflammatory agents for symptoms of schizophrenia.
|
J Psychopharmacol
|
2012
|
1.04
|
|
17
|
Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients.
|
Psychopharmacol Bull
|
2007
|
1.01
|
|
18
|
Diagnostic criteria for cannabis withdrawal syndrome.
|
Drug Alcohol Depend
|
2011
|
1.00
|
|
19
|
Increased prevalence of transglutaminase 6 antibodies in sera from schizophrenia patients.
|
Schizophr Bull
|
2012
|
0.95
|
|
20
|
Case report on the management of depression in schizoaffective disorder, bipolar type focusing on lithium levels and measurement-based care.
|
J Nerv Ment Dis
|
2011
|
0.95
|
|
21
|
Elevated gliadin antibody levels in individuals with schizophrenia.
|
World J Biol Psychiatry
|
2013
|
0.95
|
|
22
|
Novel factor-based symptom scores in treatment resistant schizophrenia: implications for clinical trials.
|
Neuropsychopharmacology
|
2002
|
0.94
|
|
23
|
A gluten-free diet in people with schizophrenia and anti-tissue transglutaminase or anti-gliadin antibodies.
|
Schizophr Res
|
2012
|
0.92
|
|
24
|
Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia.
|
Clin Neuropharmacol
|
2005
|
0.92
|
|
25
|
Rehospitalization risk with second-generation and depot antipsychotics.
|
Ann Clin Psychiatry
|
2003
|
0.91
|
|
26
|
Antagonist-elicited cannabis withdrawal in humans.
|
J Clin Psychopharmacol
|
2011
|
0.91
|
|
27
|
Quetiapine at high doses for the treatment of refractory schizophrenia.
|
Schizophr Res
|
2008
|
0.90
|
|
28
|
Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial.
|
Schizophr Res
|
2011
|
0.89
|
|
29
|
Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study.
|
J Clin Psychiatry
|
2006
|
0.88
|
|
30
|
Tobacco craving in smokers with and without schizophrenia.
|
Schizophr Res
|
2010
|
0.87
|
|
31
|
Oral fluid and plasma cannabinoid ratios after around-the-clock controlled oral Δ(9)-tetrahydrocannabinol administration.
|
Clin Chem
|
2011
|
0.86
|
|
32
|
Bone mineral density and osteoporosis risk in older patients with schizophrenia.
|
J Clin Psychopharmacol
|
2011
|
0.86
|
|
33
|
Clinical characteristics of heavy and non-heavy smokers with schizophrenia.
|
Schizophr Res
|
2012
|
0.85
|
|
34
|
Cervical cancer screening and acute care visits among Medicaid enrollees with mental and substance use disorders.
|
Psychiatr Serv
|
2012
|
0.85
|
|
35
|
Cannabis withdrawal in chronic cannabis users with schizophrenia.
|
J Psychiatr Res
|
2012
|
0.84
|
|
36
|
Alcohol and cannabis use and mortality in people with schizophrenia and related psychotic disorders.
|
J Psychiatr Res
|
2012
|
0.84
|
|
37
|
Around-the-clock oral THC effects on sleep in male chronic daily cannabis smokers.
|
Am J Addict
|
2013
|
0.84
|
|
38
|
Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms.
|
Schizophr Res
|
2011
|
0.83
|
|
39
|
Role of chronic stress and depression in periodontal diseases.
|
Periodontol 2000
|
2014
|
0.83
|
|
40
|
Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine.
|
Neuropsychopharmacology
|
2010
|
0.83
|
|
41
|
Circumstances of suicide among individuals with schizophrenia.
|
Schizophr Res
|
2002
|
0.83
|
|
42
|
A Randomized Clinical Trial of Oxytocin or Galantamine for the Treatment of Negative Symptoms and Cognitive Impairments in People With Schizophrenia.
|
J Clin Psychopharmacol
|
2017
|
0.82
|
|
43
|
Reduced arterial compliance in patients with psychiatric diagnoses.
|
Schizophr Res
|
2012
|
0.82
|
|
44
|
Tolerance to effects of high-dose oral δ9-tetrahydrocannabinol and plasma cannabinoid concentrations in male daily cannabis smokers.
|
J Anal Toxicol
|
2012
|
0.82
|
|
45
|
The effects of galantamine on psychopathology in chronic stable schizophrenia.
|
Clin Neuropharmacol
|
2009
|
0.81
|
|
46
|
Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine.
|
Clin Schizophr Relat Psychoses
|
2011
|
0.81
|
|
47
|
Deaths from diabetic ketoacidosis after long-term clozapine treatment.
|
Am J Psychiatry
|
2003
|
0.80
|
|
48
|
Adjunctive quetiapine decreases symptoms of tardive dyskinesia in a patient taking risperidone.
|
Clin Neuropharmacol
|
2003
|
0.80
|
|
49
|
Exercise program adherence using a 5-kilometer (5K) event as an achievable goal in people with schizophrenia.
|
Biol Res Nurs
|
2010
|
0.80
|
|
50
|
Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research.
|
Schizophr Bull
|
2008
|
0.80
|
|
51
|
Prevalence of childhood physical and sexual abuse in veterans with psychiatric diagnoses.
|
J Nerv Ment Dis
|
2013
|
0.79
|
|
52
|
Predictive model accuracy in estimating last Δ9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC.
|
Drug Alcohol Depend
|
2012
|
0.79
|
|
53
|
Perception of depot antipsychotics by mental health professionals.
|
J Psychiatr Pract
|
2003
|
0.79
|
|
54
|
Cardiovascular disease in relation to weight in deceased persons with schizophrenia.
|
Compr Psychiatry
|
2005
|
0.78
|
|
55
|
CB1 - cannabinoid receptor antagonist effects on cortisol in cannabis-dependent men.
|
Am J Drug Alcohol Abuse
|
2011
|
0.78
|
|
56
|
Psychotropic prescribing for acute inpatient admissions in patients with severe psychosis.
|
J Clin Psychopharmacol
|
2004
|
0.78
|
|
57
|
The Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use.
|
J Dual Diagn
|
2012
|
0.77
|
|
58
|
Current status of antipsychotic treatment.
|
Curr Drug Targets CNS Neurol Disord
|
2002
|
0.77
|
|
59
|
Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine.
|
J Clin Psychiatry
|
2003
|
0.76
|
|
60
|
Illicit drug use in heavy smokers with and without schizophrenia.
|
Schizophr Res
|
2012
|
0.76
|
|
61
|
The effects of clozapine and high-dose olanzapine on brain function in treatment-resistant schizophrenia: a case study.
|
J Psychopharmacol
|
2004
|
0.76
|
|
62
|
Aripiprazole treatment causes extrapyramidal side effects but not prolactin elevation: a disconnect of the striatal D2 occupancy story: case report.
|
J Clin Psychopharmacol
|
2008
|
0.76
|
|
63
|
Tardive dyskinesia predicts prolactin response to buspirone challenge in people with schizophrenia.
|
J Neuropsychiatry Clin Neurosci
|
2005
|
0.76
|
|
64
|
The prevalence of hyperprolactinemia after long-term haloperidol use in patients with chronic schizophrenia.
|
J Clin Psychopharmacol
|
2005
|
0.76
|
|
65
|
Evaluating sexual function in patients with treatment-resistant schizophrenia.
|
Schizophr Res
|
2003
|
0.76
|
|
66
|
Olanzapine and risperidone.
|
Am J Health Syst Pharm
|
2003
|
0.75
|
|
67
|
Kynurenine and Tryptophan Levels in Patients With Schizophrenia and Elevated Antigliadin Immunoglobulin G Antibodies.
|
Psychosom Med
|
2016
|
0.75
|
|
68
|
Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study.
|
J Clin Psychopharmacol
|
2013
|
0.75
|
|
69
|
Electrochemical study of the catechol-modified chitosan system for clozapine treatment monitoring.
|
Langmuir
|
2014
|
0.75
|
|
70
|
T. Kishi and N. Iwata: Varenicline for smoking cessation in people with schizophrenia: systematic review meta-analysis.
|
Eur Arch Psychiatry Clin Neurosci
|
2014
|
0.75
|
|
71
|
The risk of suicide after clozapine discontinuation: Cause for concern.
|
Ann Clin Psychiatry
|
2015
|
0.75
|
|
72
|
Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection.
|
J Cent Nerv Syst Dis
|
2011
|
0.75
|
|
73
|
Comparison of clozapine response for inpatients in the research setting versus routine clinical practice.
|
Psychiatr Q
|
2008
|
0.75
|
|
74
|
The relationship of brain weight to body mass index (BMI) upon autopsy in young people with severe mental illness.
|
Schizophr Res
|
2010
|
0.75
|
|
75
|
Discontinuation of risperidone, olanzapine, and haloperidol in first-episode psychosis.
|
J Clin Psychopharmacol
|
2007
|
0.75
|
|
76
|
Anti-inflammatory Combination Therapy for the Treatment of Schizophrenia.
|
J Clin Psychopharmacol
|
2020
|
0.75
|
|
77
|
Cortisol response to buspirone in extended abstinent alcoholics.
|
Alcohol Alcohol
|
2004
|
0.75
|
|
78
|
A new blood-based diagnostic aid for schizophrenia.
|
Psychiatr Serv
|
2011
|
0.75
|